Results 91 to 100 of about 27,341 (230)

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, EarlyView.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2203-2211, July 2026.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

Combined Effects of Ezetimibe and Phytosterols on Cholesterol Metabolism

, 2011
Background— Both ezetimibe and phytosterols inhibit cholesterol absorption. We tested the hypothesis that the combination of ezetimibe and phytosterols is more effective than ezetimibe alone in altering cholesterol metabolism.
Xiaobo Lin, Karen Steger-May, Lina Ma, Richard E. Ostlund, Michael Lefevre, Susan B. Racette, Catherine Anderson Spearie   +6 more
core   +1 more source

The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia

Lipids in Health and Disease, 2004
Elevated low-density lipoprotein (LDL)-cholesterol is associated with a significantly increased risk of coronary heart disease. Ezetimibe is the first member of a new class of selective cholesterol absorption inhibitors.
Suleiman Ehab S, Choueiri Nabil E, Al-Shaer Moutasim H   +2 more
doaj   +1 more source

Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods

Chirality, Volume 38, Issue 7, July 2026.
Chirality is crucial in drug development since both biological targets in the organism and the majority of pharmaceutical compounds are chiral. The synthesis and resolution of chiral compounds are critical steps while developing chiral drugs. Asymmetric synthesis and racemic resolution are the two most common methods for obtaining enantiopure drugs ...
Burcu Karayavuz, Cigdem Karaaslan Kirmizioglu   +1 more
wiley   +1 more source

Ezetimibe inhibits the migration and invasion of triple‐negative breast cancer cells by targeting TGFβ2 and EMT

FEBS Open Bio
The important role of cholesterol in tumor metastasis has been widely studied in recent years. Ezetimibe is currently the only selective cholesterol uptake inhibitor on the market.
Lingkai Kong, Qinyu He, Ding Ma, Weiwei Shi, Qilei Xin, Chunping Jiang, Junhua Wu   +6 more
doaj   +1 more source

Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2015
BackgroundRandomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe ...
Alessandro Battaggia, Alberto Donzelli, Maria Font, Davide Molteni, Antonio Galvano   +4 more
doaj   +1 more source

Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature

Lipids in Health and Disease, 2020
The aim of this study was to compare and summarize the lipid-altering effects of combination therapy with ezetimibe and statins (E/S) and a double dose of statin (D/S) monotherapy on patients with hypercholesterolemia.
Min Yu, Chunshui Liang, Qianran Kong, Yihan Wang, Minmin Li   +4 more
semanticscholar   +1 more source

Fluorinative Olefin Bond Functionalization of Selected Functionalized Cycloalkenes

Israel Journal of Chemistry, Volume 66, Issue 4, July 2026.
Palladium‐catalyzed ring olefin bond difunctionalization, through functional group and substrate‐dependent arylfluorination, of selected functionalized cycloalkenes has been studied. Palladium‐catalyzed ring olefin bond difunctionalization through arylfluorination of selected five‐, six‐, and seven‐membered functionalized cycloalkenes has been studied.
Tamás T. Novák, Tamás Holczbauer, Máté Sulyok‐Eiler, Pál T. Szabó, Melinda Nonn, Gábor Turczel, Anas Semghouli, Santos Fustero, Jianlin Han, Gábor Hornyánszky, Loránd Kiss   +10 more
wiley   +1 more source

The ezetimibe controversy: implications for clinical practice

, 2011
Low-density lipoprotein cholesterol (LDL-C) remains the primary target of lipid-lowering therapy. Achieving LDL-C goals as outlined by the National Cholesterol Education Program Adult Treatment Panel III can be difficult with statins alone; therefore ...
Ujjaini Khanderia, Randolph E. Regal, Thomas Boyden, Melvyn Rubenfire   +3 more
core   +1 more source